PubMed HealthSearch

PubMed · 1620814

Mortality in systemic sclerosis (scleroderma).

Abstract

Two hundred and thirty-seven patients with systemic sclerosis were followed prospectively in a scleroderma clinic. The overall 3, 6, and 9-year survival rates were 86, 76 and 61 per cent respectively. Renal, cardiac and pulmonary disease, and older age at enrollment were adverse prognostic factors associated with reduced survival. There were no significant differences in survival between males and females or in patients with restricted compared to those with diffuse skin thickening. Death from systemic sclerosis was most frequently due to pulmonary hypertension, with fewer than expected deaths from renal or cardiac causes. Twenty-eight per cent of deaths were due to causes unrelated to systemic sclerosis, most commonly cancer and ischaemic heart disease, and in older patients.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

P Lee, P Langevitz, C A Alderdice, M Aubrey, P A Baer, M Baron, D Buskila, J P Dutz, I Khostanteen, S Piper. 1992. Mortality in systemic sclerosis (scleroderma).. https://pubmed.ncbi.nlm.nih.gov/1620814/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Cardiac allograft arteriopathy: an ischemic burden of a different sort.

As heart transplant recipients live longer, an accelerated and distinct form of coronary artery disease develops that adversely affects survival. Indeed, cardiac allograft arteriopathy may be detected in as many as 90% of heart transplant recipients after 5 years. The precise incidence is not easily determined because the disease can be difficult to recognize when noninvasive tests are used; even angiography has substantive limitations. The distinct characteristics of this type of coronary artery disease result in a different form of chronic ischemic syndrome. The angiographic hallmark of allograft arteriopathy is an extensive, diffuse, obliterative process that primarily involves distal, small, subendocardial arteries. Endothelial injury seems to trigger the disease process. The arteriopathy is likely immunologically mediated and promoted or exacerbated by traditional atherosclerotic disease risk factors. Viral infection may be involved as well. To gain a better understanding of allograft arteriopathy, it is worthwhile to review its incidence, pathophysiology, prognosis, prevention, and treatment.

Coronary Disease